{"id":104969,"date":"2026-02-16T05:03:07","date_gmt":"2026-02-16T05:03:07","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/"},"modified":"2026-02-16T05:03:07","modified_gmt":"2026-02-16T05:03:07","slug":"sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/","title":{"rendered":"Sapu Bioscience Expands International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway"},"content":{"rendered":"
\n

SAN DIEGO, CA, Feb. 16, 2026 (GLOBE NEWSWIRE) — Sapu Bioscience<\/strong> today announced advancements in its global IP portfolio supporting OT-101<\/strong>, its proprietary TGF-\u03b2 antisense therapeutic platform, strengthening protection across neurology, oncology, and CNS drug delivery.<\/p>\n

Background on OT-101<\/strong><\/p>\n

OT-101 (TGF-\u03b2 antisense inhibitor) is a clinical-stage therapeutic with prior oncology trials including glioblastoma and pancreatic cancers. The Company is advancing OT-101 as a CNS-capable therapeutic platform, supported by targeted delivery technologies and expanded IP coverage.<\/p>\n

Parkinson\u2019s Disease<\/strong><\/p>\n

In Australia, the Company has received allowed patent claims covering OT-101 (SEQ ID NO:9) for treating Parkinson\u2019s Disease, including excessive daytime sleepiness and insomnia. The claims cover methods of treatment, manufacture-of-medicament claims, and CNS delivery routes including intrathecal and intracranial infusion.<\/p>\n

Intracranial Delivery Device<\/strong><\/p>\n

In China and Germany, utility model patents for \u201cDevice for Delivering Fluid Pharmaceutical Compositions by Intracranial Continuous Infusion\u201d have been granted (CN 222693486 U, effective April 1, 2025; DE 21 2023 000 368.6, term through 2033), providing device-level protection for continuous intracranial infusion technologies.<\/p>\n

Strategic Impact<\/strong><\/p>\n

These IP developments establish an integrated OT-101 CNS commercialization platform combining therapeutic use claims with granted delivery-device protection, enhancing OT-101\u2019s strategic value for development, partnering, and commercialization.<\/p>\n

Management Commentary<\/strong><\/p>\n

\u201cThese patent grants represent a pivotal inflection point for OT-101\u2019s development,\u201d said Dr. Vuong Trieu, CEO<\/strong>. \u201cBy securing method-of-treatment claims for Parkinson\u2019s Disease alongside granted device patents for intracranial delivery, we have built an integrated IP fortress around our CNS strategy, positioning OT-101 as a fully protected platform\u2014from molecule to delivery device\u2014ready for strategic partnering and clinical advancement.\u201d<\/p>\n

The Company will present at BIO-Europe Spring on March 23\u201325, 2026, featuring data on OT-101 and its Deciparticle\u2122<\/sup> leading candidate: Sapu003 \u2013 intravenous everolimus.<\/p>\n

About OT-101<\/strong><\/p>\n

OT-101 is a clinical-stage TGF-\u03b2 antisense inhibitor with clinical history in glioblastoma and pancreatic cancer, now advanced as a CNS-capable therapeutic platform with expanded IP protection.<\/p>\n

About the Deciparticle<\/strong>\u2122<\/strong><\/sup> Platform<\/strong><\/p>\n

The Deciparticle\u2122<\/sup> platform is a proprietary nanotechnology encapsulating hydrophobic molecules as sub-20 nm nanoparticles for intravenous administration, improving systemic exposure and enabling precision delivery at clinical scale.<\/p>\n

About Sapu Bioscience<\/strong><\/p>\n

Sapu Bioscience is a clinical-stage biotechnology company advancing proprietary platforms in oncology and neurology, including OT-101 and the Deciparticle\u2122<\/sup> nanomedicine platform, with an ISO-5 cGMP manufacturing facility.<\/p>\n

For more information, visit www.sapubio.com<\/u><\/a>.<\/p>\n

Contact Information:<\/strong><\/p>\n

For Sapu Bioscience:
Investor Relations
ir@sapubio.com<\/u><\/a><\/p>\n

\n <\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO, CA, Feb. 16, 2026 (GLOBE NEWSWIRE) — Sapu Bioscience today announced advancements in its global IP portfolio supporting OT-101, its proprietary TGF-\u03b2 antisense therapeutic platform, strengthening protection across neurology, oncology, and CNS drug delivery. Background on OT-101 OT-101 (TGF-\u03b2 antisense inhibitor) is a clinical-stage therapeutic with prior oncology trials including glioblastoma and pancreatic […]<\/p>\n","protected":false},"author":2,"featured_media":104970,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/c9ad92c0-50db-402a-ac79-286559cd6e39","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-104969","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t